Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Nick who wrote (3061)	6/12/1998 6:48:00 PM
From: jpbrody	Read Replies (1) \| Respond to of 5736

SPRX is following a more conventional path to bringing a medical diagnostic product to market. CCSI got the colormate III approved for sale in the US by the FDA. I believe this is a briefcase sized device. One of the many bizarre parts of this story is that they have no intention of marketing the colormate III. They are going to market a handheld device. That means they have to go back to the FDA and get that approved. Most diagnostic testing companies will finalize the product and it's manufacturing before going through the FDA process. Why? Because there's no reason to have FDA approval until you are ready to sell the thing. I think CCSI has stated that the FDA approval on CCSI gave them respectability or something to that effect. Most people in the industry would look at it as rather unconventional business practice. For the conspiracy theorists here, any idea why CCSI called a special meeting in February of this year to vote on a 3/2 split of this stock when it hit the high price of $15/share? They could have waited for the regular annual meeting in May/June which seems to have been cancelled because of the special meeting.

To: Nick who wrote (3061)	6/12/1998 6:51:00 PM
From: Robin	Respond to of 5736

Nick, In the overall scheme of things, it does not matter. As I said in my post #3052, the big return for SPRX is in products related to diabetic maintenance. The maintenance of diabetes represents the largest disposable market in the US medical industry as well as throughout the world, and the first to successfully develop and market a minimally or non-invasive product for diabetes will take over the majority of the market. The bilirubin market is small potatoes compared to this and this is where the payoff in SPRX will come if they are successful. For the record, I do not consider SPRX worth $7/share for the 'bili' product solely and also do not consider CCSI worth it's present $7 as well based solely on this product and any others they might develop. The major difference to me right now is who has enough money to get out product #2 if their 'bili' product either doesn't work or has a market that doesn't materialize to their expectations. For SPRX, there is enough cash in the bank to get them there. 'Bili' represents a small amount of revenue and well needed experience on the way to developing a product for diabetes. For CCSI, the 'bili' product had better work and the market had better materialize, or it's 'Good-Bye, Money'! As for CCSI being in the final stages of the deal, at this point I would consider Darby fortunate if she could manage to find a company that would acquire CCSI, that's the deal I would look for if I were long. Is there no market for Colormate or Bilichek? No. It's just that the bilirubin market simply does not justify a price of $7/share for either SPRX or CCSI. Nick, why not consider swapping your CCSI position for SPRX 1:1 on Monday. I am sure if you do (assuming CCSI isn't under attack again) you will thank me some day. Just wish they were writing puts on this thing! Woulda' bought em when CCSI was at $13. Rockin' Robin